2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Blood Banking, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Vaccines, Non-Biological Therapies, Opioids, Women’s Health, Adverse Events, Biological Processes, Hematopoiesis, Metabolism, Clinical Practice (Health Services and Quality), Patient Safety, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Thalassemia, Immunology, Immunodeficiency, Infectious Diseases, Bacterial, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

4696 Hip-level surgical treatment pathways and outcomes of avascular necrosis of the femoral head in children, adolescents, and young adults with sickle cell disease

Khalid Elsir Elbashir, MD, MPH, Parul Rai, MD2, Yogindra Persaud, MD3, Alexis Leonard, MD4, Ragha Srinivasan, MPH5, Tomas Bryndziar, MD6, Jahnavi Gollamudi, MD7, Babette Zemel, PhD8, Pei-Lin Chen, MPH9, Michael Neel, MD10, Deepika Darbari, MD11, Guolian Other Person Kang, PhD12, Jeffrey Gossett, MS13, Clifford Takemoto, MD14, Oyebimpe Adesina, MD,MS15
1 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
2 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
3 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
4 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
5 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
6 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
7 University of Cincinnati, Cincinnati, Ohio, United States
8 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
9 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
10 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
11 Children's National Hospital,, Washington, DC, District of Columbia, United States
12 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
13 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
14 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
15 UC Davis, Sacramento, California, United States

Background: Avascular necrosis of the femoral head (AVNFH) is a debilitating complication of sickle cell disease (SCD) that can progress to femoral head collapse requiring arthroplasty. We evaluated surgical treatment pathways and outcomes among children, adolescents, and young adults (AYA) with SCD-associated AVNFH. At St. Jude Children’s Research Hospital, management of AVNFH in children and AYA with SCD is guided by symptoms, extent of femoral head involvement, and Steinberg stage. Depending on disease severity, patients may undergo conservative management, hip-preserving procedures including core decompression (CD) with or without bone marrow aspirate concentrate (BMAC), or arthroplasty (hemiarthroplasty, hip resurfacing, or total hip arthroplasty [THA]) for advanced collapse. However, surgical outcomes and optimal treatment strategies for AVNFH in children and AYA with SCD remain poorly characterized.

Methods: We evaluated participants enrolled in the Sickle Cell Clinical Research and Intervention Program (SCCRIP; NCT02098863; n=825) between 2001 and 2022. Participants undergoing pelvic MRI for hip pain were identified, and those with non-SCD causes of hip pain were excluded. Demographic, genotype, laboratory, radiologic, surgical, and opioid utilization data were obtained from SCCRIP and supplemented by chart review. Analyses were performed at both patient and hip levels. Surgical procedures were classified as hip-preserving or arthroplasty. Treatment pathways, laterality, progression to arthroplasty, longitudinal follow-up, and opioid utilization before and after intervention were evaluated. Hip-level treatment trajectories were visualized using Sankey and swimmer plots to characterize procedural sequencing, progression to arthroplasty, and longitudinal follow-up.

Results: Among 825 SCCRIP participants, 104 (12.6%) underwent pelvic MRI for hip pain and 53 (51.0%) had MRI-confirmed AVNFH, corresponding to an overall prevalence of 6.4%. Median age at AVNFH diagnosis was 15.1 years (IQR, 12.3-17.0). A total of 87 AVNFH hips were identified, including 68 (78%) with bilateral involvement and 19 (22%) with unilateral involvement. Among 53 patients with AVNFH, 23 (43%) required surgical intervention. These patients contributed 40 AVNFH-involved hips, including 34 treated hips and 6 hips managed non-operatively. Among the 34 treated hips, 25 (74%) underwent hip-preserving procedures and 9 (26%) underwent direct arthroplasty. Of the 25 hips treated with hip-preserving procedures, 20 (80%) did not progress to arthroplasty during follow-up, whereas 5 (20%) subsequently required arthroplasty. Surgical intervention was more common among patients with bilateral than unilateral involvement (82% vs. 76%). Among the 34 treated hips, 24 (71%) were male and 10 (29%) were female. Arthroplasty occurred in 12 of 24 male hips (50%) compared with 2 of 10 female hips (20%). Progression to arthroplasty occurred in 2 of 8 hips (25%) treated with CD alone and 3 of 17 hips (17.6%) treated with CD+BMAC. Mean follow-up following radiologic diagnosis was 6.1 years (median 4.8 years; range 1.9-13.7 years).

Conclusion: Bilateral AVNFH accounted for 78% of affected hips, and 43% of patients required surgical intervention. Arthroplasty occurred more frequently in male than female hips. Hip-preserving procedures prevented progression to arthroplasty in 80% of treated hips during approximately six years of follow-up, supporting their role as an important intermediary treatment strategy. Progression to arthroplasty appeared less frequent following CD+BMAC than CD alone, although larger prospective multicenter studies are needed to define optimal patient selection and timing of intervention.

Khalid Elsir Elbashir, MD, MPH: No relevant conflicts of interest to declare.